Compare Stocks → Incredible Opportunity to Retire FAST! (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:BPMUFNASDAQ:CARANASDAQ:EOLSNASDAQ:KZR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPMUFBasilea Pharmaceutica$44.45$41.34$38.60▼$44.45$526.79M0.655 shsN/ACARACara Therapeutics$0.70-3.5%$0.82$0.50▼$4.67$38.53M0.7650,971 shs5,329 shsEOLSEvolus$11.83+0.9%$13.55$7.07▼$15.43$685.43M1.45614,016 shs6,935 shsKZRKezar Life Sciences$0.81-2.1%$0.89$0.67▼$3.13$58.60M0.47700,064 shs2,050 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPMUFBasilea Pharmaceutica0.00%0.00%+9.08%+8.41%-14.52%CARACara Therapeutics+10.50%+2.87%-17.31%+28.14%-82.19%EOLSEvolus+1.65%-1.43%-15.13%-0.26%+28.09%KZRKezar Life Sciences+4.05%+1.54%-15.65%+0.24%-66.99%The "Smart Money" Is Ready for May 1st Are You? (Ad)Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. One Former Wall St. Trader Explains Why…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AN/AN/AN/ACARACara Therapeutics3.9515 of 5 stars3.42.00.04.22.01.71.3EOLSEvolus4.1225 of 5 stars3.53.00.03.52.72.50.6KZRKezar Life Sciences3.9085 of 5 stars3.22.00.04.61.91.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPMUFBasilea PharmaceuticaN/AN/AN/AN/ACARACara Therapeutics2.75Moderate Buy$9.751,283.17% UpsideEOLSEvolus3.00Buy$20.6074.13% UpsideKZRKezar Life Sciences2.33Hold$11.001,266.46% UpsideCurrent Analyst RatingsLatest BPMUF, KZR, EOLS, and CARA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/10/2024EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.003/28/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/15/2024KZRKezar Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/6/2024CARACara TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/5/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/1/2024EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.001/29/2024EOLSEvolusBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$10.00 ➝ $16.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPMUFBasilea Pharmaceutica$175.50M3.00$1.13 per share39.34($0.94) per share-47.29CARACara Therapeutics$20.97M1.84N/AN/A$1.05 per share0.67EOLSEvolus$202.09M3.39N/AN/A($0.36) per share-32.86KZRKezar Life Sciences$7M8.37N/AN/A$2.58 per share0.31Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPMUFBasilea Pharmaceutica$11.64MN/A0.0014.92N/AN/AN/AN/AN/ACARACara Therapeutics-$118.51M-$2.18N/AN/AN/A-565.21%-122.10%-89.64%5/20/2024 (Estimated)EOLSEvolus-$61.69M-$1.09N/AN/AN/A-30.52%N/A-32.19%5/14/2024 (Estimated)KZRKezar Life Sciences-$101.87M-$1.41N/AN/AN/AN/A-43.08%-37.59%5/9/2024 (Estimated)Latest BPMUF, KZR, EOLS, and CARA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023KZRKezar Life Sciences-$0.39-$0.35+$0.04-$0.26N/AN/A3/7/2024Q4 2023EOLSEvolus-$0.15-$0.20-$0.05-$0.19$61.14 million$61.00 million3/4/202412/31/2023CARACara Therapeutics-$0.57-$0.59-$0.02-$0.59$2.34 million$3.00 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPMUFBasilea PharmaceuticaN/A3.202.64CARACara TherapeuticsN/A4.544.43EOLSEvolusN/A2.332.10KZRKezar Life Sciences0.0511.6611.66OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPMUFBasilea PharmaceuticaN/ACARACara Therapeutics44.66%EOLSEvolus90.69%KZRKezar Life Sciences67.90%Insider OwnershipCompanyInsider OwnershipBPMUFBasilea PharmaceuticaN/ACARACara Therapeutics4.20%EOLSEvolus5.40%KZRKezar Life Sciences7.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBPMUFBasilea Pharmaceutica14711.85 millionN/ANot OptionableCARACara Therapeutics5554.66 million52.36 millionOptionableEOLSEvolus27357.94 million54.82 millionOptionableKZRKezar Life Sciences5872.80 million67.05 millionNot OptionableBPMUF, KZR, EOLS, and CARA HeadlinesSourceHeadlineKezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Up 5.6% in Marchamericanbankingnews.com - April 16 at 1:26 AMKezar Life Sciences (NASDAQ:KZR) Trading Down 6.2%marketbeat.com - April 16 at 12:43 AMKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)businesswire.com - April 8 at 4:01 PMFrom Pennies to Fortunes: 3 Stocks Set to Make Millionairesinvestorplace.com - March 27 at 4:30 PMDiamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026investorplace.com - March 16 at 6:56 AMKZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023investorplace.com - March 14 at 10:03 PMKezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updatebusinesswire.com - March 14 at 4:01 PMEverest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefeconfinanznachrichten.de - March 12 at 3:21 PMKezar Life Sciences, Inc. (KZR)finance.yahoo.com - March 3 at 2:56 PMKezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conferencefinance.yahoo.com - February 28 at 5:39 PMEverest Medicines & Kezar Life Sciences receive China NMPA nod to begin phase 2b PALIZADE trial of zetomipzomib in patients with lupus nephritispharmabiz.com - February 28 at 2:37 AMBuy Rating Affirmed for Kezar Life Sciences Amidst Progress in Lupus Nephritis Treatment and Expansion into Chinese Marketmarkets.businessinsider.com - February 27 at 4:36 PMEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritisbusinesswire.com - February 26 at 6:30 PMEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritisprnewswire.com - February 26 at 6:10 PM3 Top Penny Stocks for 5,000% Upside in 2024 and Beyondinvestorplace.com - February 25 at 2:12 PMKezar Life Sciences Stock (NASDAQ:KZR) Dividends: History, Yield and Datesbenzinga.com - February 22 at 12:59 AMKezar Life Sciences Inc.thestreet.com - February 19 at 7:24 PM3 Penny Stocks Poised for an Unbelievable 1,000% Jumpfinance.yahoo.com - February 10 at 9:24 AMKezar Life Sciences Inc KZRmorningstar.com - January 31 at 6:24 PMKZR Jan 2025 17.500 callfinance.yahoo.com - January 18 at 5:16 PMKezar Life Sciences: Results Of Operations And Financial Conditioncbonds.com - January 10 at 1:58 PMBull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growthfinance.yahoo.com - December 26 at 8:31 AMKezar Life Sciences: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listingcbonds.com - December 6 at 10:38 AMEverest inches towards clinical studies for renal disease drug in Chinamsn.com - December 5 at 2:26 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBasilea PharmaceuticaOTCMKTS:BPMUFBasilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.Cara TherapeuticsNASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.EvolusNASDAQ:EOLSEvolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Kezar Life SciencesNASDAQ:KZRKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.